Ovarian Cancer Coverage From Every Angle

Recent News

Potential Assays for Pinpointing Ovarian, Endometrial Cancers
Do Patients With Low-Grade Serous Ovarian Carcinoma Benefit From Targeted Sequencing?
‘Sticky Webs of DNA’ in Pathogenesis of Ovarian Cancer
FDA Approves Olaparib for First-Line Maintenance of BRCA-Mutated, Advanced Ovarian Cancer
Novel Vascular Technique Being Studied in Advanced Ovarian Cancer
Shedding Light on Resistance to PARP Inhibitors in Patients With Ovarian Cancer
NICE Rejects Olaparib Tablets in Ovarian Cancer Maintenance Therapy
Durvalumab Plus Olaparib in BRCA-Mutant Ovarian Cancer
Apatinib After Second-Line Chemotherapy Failure in Advanced Ovarian Cancer
ESMO 2018: Doxorubicin vs. Gemcitabine in Bevacizumab-Based Therapy for Ovarian Cancer
Priority Review Granted by FDA to Olaparib Maintenance Therapy for Some Patients With Ovarian Cancer
ESMO 2018: Novel Combination Therapy for Platinum-Resistant Ovarian Cancer
ESMO 2018: Early Results With Oregovomab/Nivolumab in Recurrent Ovarian Cancer
ESMO 2018: Niraparib in Resistant Subsets of Ovarian Cancer
ESMO 2018: New Compound Active in Treatment of Platinum-Resistant Ovarian Cancer
ESMO 2018: ‘Outstanding’ Results With Olaparib Maintenance in Advanced Ovarian Cancer
Novel Angiogenic Target to Combat Adaptive Resistance
Immunotherapy Combination Active in Ovarian Cancer
International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers
Ovarian Cancer Research Symposium: Stromal Cell Expression and Metastasis
Ovarian Cancer Research Symposium: Heterogeneity of Cancer-Associated Fibroblasts
Ovarian Cancer Research Symposium: Role of Antiapoptotic Genes in Chemotherapy Resistance
Ovarian Cancer Research Symposium: Acquired Resistance to PARP Inhibitors
Ovarian Cancer Research Symposium: Is ATR Worthy Target in Resistant Disease?
Ovarian Cancer Research Symposium: Early Results With Immunotherapy Combination
Ovarian Cancer Research Symposium: Biomarkers for Early Detection
Phase II Trial Answers Bevacizumab + Everolimus Question in Resistant Ovarian Cancer
Can m-TORC1/2 Inhibitor Added to Chemotherapy Improve Outcomes in Ovarian Cancer?
Combination of Apatinib and Oral Etoposide in Resistant Ovarian Cancer
Shedding New Light on Resistance to PARP Inhibitors in Ovarian Cancer
Does Fertility Treatment Increase Risk of Ovarian Cancer?
FDA Grants Fast Track Designation to AVB-S6-500 for Recurrent Ovarian Cancer
Preclinical Study Focuses on Metastatic Process in High-Grade Ovarian Cancer
Breakthrough Device Designation Granted by FDA to Liquid Biopsy
Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer
Secondary Cytoreductive Surgery for Epithelial Ovarian Cancer
Does Olaparib Increase the Risk of MDS/AML in Patients Treated for Relapsed Ovarian Cancer?
ESHRE 2018: Early-Stage Research on Artificial Ovary for Fertility Preservation

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.